Navigation Links
FDA Approves First Generic Versions of Ambien for Insomnia

The U.S. Food and Drug Administration (FDA) today approved the first generic versions of Ambien (zolpidem tartrate) immediate-release tablets.// Zolpidem (ZOLE-pi-dem) tartrate is a sedative-hypnotic drug indicated for the short-term treatment of insomnia.

"The FDA’s Office of Generic Drugs ensures that generic drugs are safe and effective for the American public through a rigorous scientific and regulatory process," said Gary J. Buehler, director, Office of Generic Drugs. "This approval offers Americans more alternatives when choosing their prescription drugs."

Zolpidem tartrate tablets in formulations of five milligrams and 10 milligrams are manufactured by multiple generic drug companies in the United States. The following 13 manufacturers have received FDA approval for zolpidem tartrate tablets: Mylan Pharmaceuticals Inc., TEVA Pharmaceuticals USA, Roxane Laboratories Inc., Watson Laboratories Inc., Ranbaxy Laboratories Ltd., Dr. Reddy’s Laboratories Ltd., Apotex Inc., Synthon Pharmaceuticals Inc., Genpharm Inc., Mutual Pharmaceutical Company Inc., Caraco Pharmaceutical Laboratories Ltd., Carlsbad Technology Inc., and Lek Pharmaceuticals.

In March, FDA requested that all manufacturers of sedative-hypnotic drug products, a class of drugs used to induce and/or maintain sleep, strengthen their product labeling to include stronger language concerning potential risks. These risks include severe allergic reactions and complex sleep-related behaviors, which may include sleep-driving. Sleep driving is defined as driving while not fully awake after ingestion of a sedative-hypnotic product, with no memory of the event.

According to the online magazine Drug Topics, in 2006, Ambien was the 13th highest selling brand name drug. The sanofi-aventis (formerly Sanofi-Synthelabo, Inc.) patent for zolpidem tartrate expired on April 21, 2007.

The FDA’s Office of Generic Drugs (OGD) reviews and decides on approval of generic drug applications.

Source: Generef.com
SM
'"/>




Related medicine news :

1. FDA Approves Contraceptive Ring
2. FDA Approves New HIV Drug, Viread
3. FDA Approves Birth Control Skin Patch
4. FDA Approves New Arthritis Drug, Bextra
5. FDA Approves Elidel Cream for Eczema
6. FDA Approves New Anti-Clotting Drug
7. FDA Approves New surgery Treatment for Farsightedness
8. FDA Approves Anti-Cancer Cell Drug - Zevalin
9. FDA Approves Remodulin for Pulmonary Hypertension
10. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
11. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/24/2017)... , ... March 24, 2017 , ... ... which will spark a conversation on the current obstacles facing infection prevention and ... completely preventable deaths caused by these infections. , The print component of ...
(Date:3/24/2017)... ... ... Texas Physical Therapy Specialists (TexPTS) is pleased to announce the opening ... is the group’s 7th location in San Antonio and 23rd in Texas. Dr. ... from the clinic, which opened March 22, 2017. , The team of ...
(Date:3/24/2017)... Pittsburgh, PA (PRWEB) , ... March 24, 2017 ... ... the Oncology Nursing Society (ONS) wanted to create a communications platform that positions ... realize this goal, Elliance and ONS reinvented their online publication as an always-on, ...
(Date:3/24/2017)... ... 24, 2017 , ... Gastro Health (“GH”) ( http://www.gastrohealth.com ... for colonoscopy at the HyGIeaCare® Center that is to be located adjacent to ... , The HyGIeaCare® Prep, cleared by the U.S. Food and Drug Administration (FDA), ...
(Date:3/24/2017)... ... 24, 2017 , ... “Vintage and Harvest A Cultivation of Christian Love” is ... residing in North Carolina with his wife, Anna Marie. He and his wife are ... David is also the author of “Shadow and Substance.” , “Love, the agape kind, ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... 24, 2017  Eli Lilly and Company (NYSE: ... invest $850 million in its U.S. operations in ... U.S. enterprise, including research laboratories, manufacturing sites, and ... driven by demand for Lilly products, as well ... development targeting cancer, pain, diabetes and other unmet ...
(Date:3/24/2017)... YORK and GENEVA , ... announced on World Tuberculosis Day revitalizes efforts to develop ... On World Tuberculosis Day, TB Alliance and ... for the clinical development of sutezolid, an antibiotic drug ... sublicense pertains to the development of sutezolid in combination ...
(Date:3/23/2017)... PUNE, India , March 23, 2017 ... are growing ageing population, increasing diabetic population, accelerating economic growth ... developments of this industry are higher life expectancy of ESRD ... potential in emerging markets. However, the expansion of the market ... ...
Breaking Medicine Technology: